Harrison.ai: Geographic Expansion

The leadership read

Harrison.ai's US entry commits it to a compliance and commercialisation burden that Australian market presence never required. FDA 510(k) or De Novo clearance pathways for AI-based diagnostic imaging software are distinct from the TGA regime the company has operated under domestically, and US hospital procurement, with its IDN structures, GPO relationships, and state-by-state reimbursement variation, bears little resemblance to the public tender environment of Australian health systems. The company has effectively created two parallel operating tracks: one continuing to mature the ANZ product and regulatory position, one starting from near-zero on US market access. This is one of twelve geographic expansion signals we have tracked across sectors in the last 90 days. The most directly comparable in AI software is Sarvam's San Francisco office opening, similarly an Asia-Pacific AI company planting a US commercial presence while its core operational base remains in-region. The consistent pattern across these moves, Sarvam, ThreatLocker's UK expansion, Sigvi into Poland, is that capital availability has moved ahead of the organisational architecture required to execute; the market-entry announcement typically precedes the leadership and compliance infrastructure by two to four quarters. Companies reaching this stage of AI health-tech expansion into the US consistently face concentrated demand in three functional areas: regulatory affairs with FDA software-as-medical-device expertise, health system commercial leadership with IDN and GPO fluency, and clinical evidence operations capable of generating the real-world performance data US payers and hospital credentialing committees require before broad deployment.